NCT03472586View on ClinicalTrials.gov

Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

May 2, 2018

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2024

Conditions
Metastatic Malignant Neoplasm in the LiverMetastatic Uveal MelanomaStage IV Uveal Melanoma AJCC v7
Interventions
BIOLOGICAL

Ipilimumab

Given IV

BIOLOGICAL

Nivolumab

Given IV

DRUG

Embolization Therapy

Undergo immunoembolization

Trial Locations (1)

19107

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER